Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA’s Pazdur Blames Trial Design Errors For Some PD-1/L1 Failures, Foreshadows Potential Agency Leniency

Jun 30 2021

• By Sarah Karlin-Smith

Richard Pazdur — Rick Pazdur And Other Oncology Center of Excellence Leaders Weighed In On Checkpoint Inhibitors

Related Content

FDA Panel Okays Keytruda’s Hepatocellular Carcinoma Indication, But Splits On Opdivo

Apr 30 2021

ODAC Report Card: Six Takeaways From Accelerated Approval Reviews Of Checkpoint Inhibitors

Apr 30 2021

EQRx Aims To Dent Saturated, But Still Expensive, PD-1 Market

May 28 2021

Related Companies

Merck & Co., Inc.

Bristol Myers Squibb Company

EQRx, Inc.

Additional Topics

United States China Asia Pacific ImmunoOncology Clinical Trials Review Pathway Post Market Regulation & Studies Biologics Regulation ASCO Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.